1. Home
  2. JCE vs PBYI Comparison

JCE vs PBYI Comparison

Compare JCE & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Core Equity Alpha Fund of Beneficial Interest

JCE

Nuveen Core Equity Alpha Fund of Beneficial Interest

HOLD

Current Price

$15.92

Market Cap

269.8M

Sector

Finance

ML Signal

HOLD

Logo Puma Biotechnology Inc

PBYI

Puma Biotechnology Inc

HOLD

Current Price

$6.06

Market Cap

263.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JCE
PBYI
Founded
2007
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
269.8M
263.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JCE
PBYI
Price
$15.92
$6.06
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
49.7K
387.6K
Earning Date
01-01-0001
02-26-2026
Dividend Yield
9.26%
N/A
EPS Growth
N/A
59.87
EPS
N/A
0.74
Revenue
N/A
$211,995,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$7.87
Revenue Growth
N/A
N/A
52 Week Low
$11.64
$2.58
52 Week High
$14.28
$6.27

Technical Indicators

Market Signals
Indicator
JCE
PBYI
Relative Strength Index (RSI) 51.99 60.41
Support Level $15.39 $5.64
Resistance Level $16.14 $6.27
Average True Range (ATR) 0.20 0.24
MACD -0.00 -0.01
Stochastic Oscillator 70.67 67.72

Price Performance

Historical Comparison
JCE
PBYI

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: